Ozempic (semaglutide) carries several serious side effects beyond the common nausea and digestive discomfort most people experience. While severe reactions are uncommon, millions of people now use this drug, which means even rare complications affect a significant number of users. Here’s what you should actually watch for.
Pancreatitis and Gallbladder Problems
Acute pancreatitis, or sudden inflammation of the pancreas, is one of the most well-documented serious risks. It tends to peak within the first 60 days of starting treatment. During this early window, nausea and appetite loss are at their worst, which means you’re eating smaller, less frequent meals. That pattern slows bile flow and promotes the formation of sludge and gallstones in the gallbladder, which can trigger pancreatitis.
Rapid weight loss compounds the problem. Losing more than about 3.3 pounds per week, or more than 25% of your body weight overall, significantly raises gallstone risk. Ozempic also directly slows the movement of bile through the biliary system, adding another layer of risk. In clinical trials, gallstones occurred in 1.5% of patients on the lower dose of Ozempic, compared to zero in the placebo group.
Signs to take seriously: severe pain in your upper abdomen that radiates to your back (pancreatitis), pain in the upper right abdomen with fever or yellowing skin (gallbladder disease), or consistently pale stools, which suggest bile isn’t flowing properly.
Stomach Paralysis and Intestinal Blockage
Ozempic works partly by slowing digestion, but in some people this effect goes too far. A large study of roughly 16 million U.S. patients found that people taking semaglutide or liraglutide had 3.67 times the risk of gastroparesis compared to those on a different weight-loss medication. Gastroparesis means the stomach loses much of its ability to push food into the small intestine, causing persistent nausea, vomiting, bloating, and abdominal pain that goes well beyond typical digestive side effects.
In October 2025, the FDA updated Ozempic’s label to include warnings for ileus (a condition where the intestine temporarily stops moving), intestinal obstruction, and severe constipation including fecal impaction. These are distinct from everyday constipation. If you develop severe abdominal pain, days without a bowel movement, or repeated vomiting, those are signs the gut has slowed to a dangerous degree.
Kidney Injury From Dehydration
Ozempic doesn’t appear to damage the kidneys directly. The problem is indirect: persistent nausea, vomiting, and diarrhea cause fluid loss, and when that dehydration becomes significant, blood flow to the kidneys drops enough to cause acute kidney injury. This risk is highest during the early weeks of dose increases, when gastrointestinal symptoms are most intense.
The drug also has mild effects on sodium handling and blood vessel tone in the kidneys, which can further reduce kidney perfusion in people who are already vulnerable. If you have existing kidney disease, take blood pressure medications that affect the kidneys, or are dealing with an illness that causes vomiting or diarrhea on top of Ozempic’s own effects, the risk climbs. Staying well-hydrated matters more on this medication than it might seem, particularly during the first months and during any dose change.
Thyroid Cancer Warning
Ozempic carries the FDA’s most serious label warning, a boxed warning, for thyroid tumors. In animal studies, semaglutide caused C-cell tumors in the thyroid, including medullary thyroid carcinoma (MTC). Whether it does the same in humans remains unknown.
Because of this uncertainty, Ozempic is completely off-limits for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic syndrome that dramatically raises MTC risk. If you notice a lump or swelling in your neck, difficulty swallowing, or persistent hoarseness while taking Ozempic, those warrant prompt evaluation.
Diabetic Retinopathy Complications
Early clinical trials of semaglutide raised concern about worsening diabetic eye disease. The SUSTAIN-6 trial flagged a higher rate of retinopathy complications in people taking the drug. However, more recent research has provided reassurance. A study published in Ophthalmology Science comparing patients on semaglutide-type drugs to those on another class of diabetes medication found no difference in retinopathy worsening after adjusting for other factors.
The current thinking is that very rapid blood sugar improvement, rather than the drug itself, may be what triggers eye problems in some people with diabetes. If you have existing diabetic retinopathy, your eye health should be monitored more closely when starting Ozempic, particularly in the first year.
Severe Allergic Reactions
Anaphylaxis and angioedema are rare but documented. Published case reports describe reactions including swelling of the lips and tongue, itchy rashes on the palms, loss of consciousness, and dangerous drops in blood pressure. Ozempic is contraindicated in anyone with a known allergy to semaglutide or any of its inactive ingredients. Because semaglutide is a once-weekly injection, an allergic reaction can develop hours after the dose, not just in the minutes immediately following it.
Mental Health Effects
Early reports raised the question of whether Ozempic might increase suicidal thoughts or behavior. The FDA conducted a thorough investigation, including a meta-analysis of 91 placebo-controlled trials covering nearly 108,000 patients and a separate real-world study of over 2.2 million users. Neither analysis found an increased risk of suicidal ideation, self-harm, depression, anxiety, or psychosis. Based on that evidence, the FDA in 2024 requested that manufacturers remove suicidal behavior warnings from the labels of this entire drug class.
That said, dramatic weight loss and changes in eating patterns can affect mood and self-image in complex ways. If your emotional state shifts significantly after starting treatment, that’s worth discussing with your prescriber, even if the drug itself isn’t chemically driving it.
Who Faces the Highest Risk
Certain groups are more vulnerable to these serious effects. People with a history of pancreatitis, gallbladder disease, or kidney problems face elevated risk of those same complications recurring or worsening. Those with a family history of medullary thyroid cancer should not take the drug at all. People who are already prone to dehydration, whether from other medications, chronic illness, or simply not drinking enough, are more likely to develop kidney problems during the adjustment period.
The first two to three months carry the most risk overall. Gastrointestinal symptoms are at their peak, the body is adjusting to slowed digestion, bile flow is changing, and rapid early weight loss can set off a chain of gallbladder problems. Gradual dose increases and consistent hydration are the most practical ways to reduce your chances of a serious complication during this window.